Manufacturer:
Takeda
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
phone:
1-855-268-1825
Approved Indication:
treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet
Conditions:
- Post-Transplant Cytomegalovirus (CMV) Infection
Therapeutic Area:
- Infectious disease